Compare Moderna, Inc. (MRNA) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Invesco Preferred ETF — how do they compare? Moderna, Inc. trades at $224.77 (market cap $78.65B), while Invesco Preferred ETF trades at $10.02 (market cap $3.60B). The key difference: Moderna, Inc. is far larger — about 21.8× Invesco Preferred ETF's market cap, and Moderna, Inc. is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Invesco Preferred ETF for 95 Days on average.
| MRNA | PGX | |
|---|---|---|
Market Cap | $78.65B | $3.60B |
Volume | 37,373,437 | 5,986,026 |
Sector | Health | — |
52-Week High | $203.46 | $11.61 |
52-Week Low | $22.36 | $9.97 |
Typical Hold Time | 59 Days | 95 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
PGX trades at $10.01, up 0.4% with bearish technical indicators showing 18 sell signals versus 3 buy signals. The stock faces resistance at $10 with RSI at neutral levels. Recent dividends of $0.06 were declared for July and September 2026, providing income potential amid technical weakness.
The outlook remains cautious with strong bearish momentum in moving averages. Investment opportunity lies in dividend yield while risks include technical breakdown below $10 support. Fundamental analysis is limited without current financial ratios, requiring updated SEC filings for proper valuation assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
